Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HTDS - Hard To Treat Diseases -- Ignore unavailable to you. Want to Upgrade?

To: jmhollen who wrote (130)	7/4/2005 10:28:56 AM
From: donpat	Read Replies (1) \| Respond to of 271

One thing, of considerable significance, to me, anyway, is that HTDS wants to sell their rights (if and when the judge permits) to the pharmaceutical company with the best offer whereas ArTec is going to make and sell Tubercin themselves. The doctor(s) assigned the US rights to the ArTec guys and they in turn sublicensed HTDS, as I understand it. Something happened - I'm not sure quite what - and there was a falling out. But the good doctor was NEVER associated with HTDS in any way himself whereas he does (or did) hold considerable shares in ArTec. Here comes the judge!